

Cite this: *Sens. Diagn.*, 2022, 1, 709Received 17th February 2022,  
Accepted 9th May 2022

DOI: 10.1039/d2sd00028h

rsc.li/sensors

Turn-on fluorescent sensors for Cu-rich amyloid  $\beta$  peptide aggregates†Yiran Huang,  Liang Sun  and Liviu M. Mirica \*

Protein misfolding and metal dishomeostasis are two key pathological factors of Alzheimer's disease. Previous studies have shown that Cu-mediated amyloid  $\beta$  (A $\beta$ ) peptide aggregation leads to the formation of neurotoxic A $\beta$  oligomers. Herein, we report a series of picolinic acid-based Cu-activatable sensors, which can be used for the fluorescence imaging of Cu-rich A $\beta$  aggregates.

The formation of extracellular amyloid plaques containing the amyloid  $\beta$  (A $\beta$ ) peptide is one of the pathological hallmarks of the brains of Alzheimer's disease (AD) patients.<sup>1,2</sup> Remarkably high concentrations (up to 20–50  $\mu$ M) of Cu and Zn have been found within these amyloid plaques,<sup>3,4</sup> and several studies have explored the interactions of metals with monomeric A $\beta$  peptides and their correlation with amyloid plaques and reactive oxygen species formation.<sup>5–11</sup> These studies show that Cu can slow down the aggregation of A $\beta$ <sub>42</sub> and reduce fibrilization to a large extent, and it is considered that Cu(II) ions can stabilize the A $\beta$ <sub>42</sub> oligomer species.<sup>12–14</sup> In this regard, novel molecules that can modulate the interaction of Cu ions with the soluble A $\beta$ <sub>42</sub> species and alleviate their neurotoxicity may serve as novel therapeutic agents for AD.<sup>15–20</sup>

In addition to the development of new therapeutic agents, it is also highly important to detect the Cu-containing A $\beta$  species in AD. A number of fluorescent sensors have been developed to probe biological copper fluxes.<sup>21–25</sup> These reporters can achieve high selectivity and signal-to-noise responses for Cu ion imaging, from cellular to tissue to whole animal settings.<sup>21,26–28</sup> However, only a few of these probes were utilized in detecting labile copper pools in AD,<sup>29,30</sup> even though countless studies have shown the

copper homeostasis is dramatically disrupted. In this regard, to understand and probe the Cu-mediated A $\beta$  aggregation process, it is significantly crucial to develop Cu–A $\beta$  specific probes. Herein, we synthesized a series of Cu-based activatable sensors aimed to potentially detect the Cu–A $\beta$  species *in vitro* and *ex vivo*. For the molecular design, we drew inspiration from Chan *et al.* who have reported the use of a 2-picolinic ester fragment that readily hydrolysed in the presence of Cu(II) but not with other divalent metal ions.<sup>25</sup> By linking the picolinic ester moiety with the A $\beta$ -binding molecular fragments, Cu(II) ions can rapidly catalyze the hydrolysis of the ester bond to generate the highly fluorescent A $\beta$  binding molecules *in vitro* (Fig. 1). Interestingly, the Cu-responsive sensors can also promptly react with Cu–A $\beta$  oligomers and fibrils, resulting in a significant fluorescence turn-on, and indicating that the probes are able to detect Cu–A $\beta$  species *in vitro*. To confirm the A $\beta$  binding specificity of the probes, brain sections from transgenic 5xFAD mice were stained with the developed sensors. As expected, when the brain sections were only stained with the compounds, the fluorescence images show




Fig. 1 a) Design and b) synthesis of Cu-based activatable sensor HYR-27; c) fluorescence turn-on effect of HYR-27 in the presence of Cu(II); [HYR-27] = 5  $\mu$ M, [Cu] = 50  $\mu$ M, pH 7.4 PBS.

Department of Chemistry, University of Illinois at Urbana-Champaign, 600 S. Mathews Avenue, Urbana, IL 61801, USA. E-mail: mirica@illinois.edu

† Electronic supplementary information (ESI) available: Experimental procedures, spectroscopic data, and copies of NMR spectra. See DOI: <https://doi.org/10.1039/d2sd00028h>



that the sensor has a poor ability to detect amyloid plaques, given the low fluorescence intensity. However, upon the addition Cu(II) ions to the medium, followed by exhaustive washing of the free unbound Cu ions, the fluorescence images clearly indicate that the Cu-responsive sensors are activated by the A $\beta$ -bound Cu(II) ions and release highly fluorescent amyloid binding fluorophores, which can specifically label the native amyloid plaques in the 5xFAD brain sections.

To detect Cu(II) in various A $\beta$  species, the developed fluorescence probes such as **HYR-27** include two components: a Cu(II)-responsive 2-picolinic ester group that chelates Cu(II) ions and selectively activates the ester bond for hydrolysis (Fig. 1),<sup>25,31</sup> and a widely-used A $\beta$ -binding molecular fragment derived from Pittsburgh compound B (PiB), which has high fluorescence intensity and can strongly interact with the A $\beta$  fibrils.

To evaluate the copper-responsive activity of the probe, we firstly performed the Cu turn-on assay in PBS, using physiologically relevant Cu concentrations typically employed in *in vitro* A $\beta$ -binding studies.<sup>12–19</sup> With the attachment of the picolinic ester moiety, the fluorescence intensity of the probe is dramatically quenched. However, when **HYR-27** was treated with Cu(II) ions, the fluorescence intensity significantly increased  $\sim$ 29 fold (Fig. 1 and S4<sup>†</sup>), indicating that the compound can coordinate to Cu(II) to facilitate the hydrolysis reaction and enhance the fluorescence intensity.

Then, we explored the Cu-activatable ability of **HYR-27** in the presence of various A $\beta$  species. When the compound was treated with A $\beta$  fibrils only, no fluorescence enhancement was observed after 30 min incubation. However, when Cu–A $\beta$  fibrils were added to the solution, the fluorescence intensity dramatically increased, likely due to the rapid Cu(II)-catalysed hydrolysis reaction (Fig. 2). Addition of excess Cu(II) ions to the solution led to a further increase in the turn-on effect

( $\sim$ 26 fold) to a fluorescence intensity similar to the one observed in the presence of only Cu(II) ions (Fig. 1). Furthermore, since Cu(II) ions were shown to stabilize the formation of A $\beta$  oligomers, which are the most neurotoxic species *in vivo*, it is also crucial to also investigate if the developed probe can also detect Cu–A $\beta$  oligomers. As a result, we first treated the compound with A $\beta$  oligomers only. Similar to the A $\beta$  fibril studies, no obvious turn-on effect was observed after 30 min incubation. Excitingly, when Cu(II) was added to the solution, the fluorescence intensity significantly increased, indicating that the probe can compete with the A $\beta$  oligomers to chelate Cu(II) and facilitate the hydrolysis reaction to release the highly fluorescent PiB probe (Fig. 2). Importantly, the Cu-mediated hydrolysis of the picolinic ester fragment is slower in the presence of the A $\beta$  aggregates (Fig. S4<sup>†</sup>), confirming that the Cu ions are indeed bound to the A $\beta$  aggregates in these *in vitro* studies, and thus mimicking the *in vivo* conditions. Overall, the Cu-dependent fluorescence turn-on studies with or without various A $\beta$  species clearly demonstrate that the developed probes can be efficiently activated by Cu(II), Cu(II)–A $\beta$  fibrils, and Cu(II)–A $\beta$  oligomers, exhibiting appreciable fluorescence turn-on *in vitro*.

To further explore the A $\beta$ -binding affinity and Cu-activatable activity of **HYR-27**, we also performed fluorescence staining studies on brain sections from 11 month-old transgenic 5xFAD mice.<sup>17</sup> Firstly, the brain sections were only stained with **HYR-27**, and the low fluorescence intensity images show that the compound cannot efficiently detect amyloid plaques (Fig. 3), which is consistent with the *in vitro* studies. To mimic the Cu-rich environment, we first treated the brain sections with 50  $\mu$ M Cu(II), followed by extensive washings with the buffer to remove any unbound Cu ions. Excitingly, performing the brain section staining following these treatment steps clearly shows that the fluorescence intensity significantly increased after the incubation with Cu(II), indicating that **HYR-27** was rapidly hydrolysed to form PiB, which can strongly bind to




Fig. 2 Cu(II) fluorescence turn-on studies of **HYR-27** toward A $\beta$  fibrils after a) 0 min and b) 30 min; Cu(II) fluorescence turn-on studies of **HYR-27** toward A $\beta$  oligomers after c) 0 min and d) 30 min. [**HYR-27**] = 5  $\mu$ M, [A $\beta$ ] = 5  $\mu$ M, [Cu] = 0–20  $\mu$ M in PBS (pH = 7.4).





Fig. 3 Fluorescence microscopy images of 5xFAD mice brain sections incubated with compounds **HYR-27** (left panel) and **HYR-27** + Cu (right panel). [**HYR-27**] = 5  $\mu$ M, [Cu] = 50  $\mu$ M. Scale bar (20 $\times$ ): 125  $\mu$ m.






**Fig. 4** Fluorescence microscopy images of 5xFAD mice brain sections incubated with compounds **HYR-27** (top left panel), **HYR-27** + Cu(II) (bottom left panel), and HJ3.4 (middle panels), and merged images (right panel). [HYR-27] = 5  $\mu$ M, [Cu] = 50  $\mu$ M, [HJ3.4] = 1  $\mu$ g ml<sup>-1</sup>. Scale bar: 125  $\mu$ m.

the native amyloid plaques in the presence of A $\beta$ -bound Cu(II) ions.

To further confirm the A $\beta$  binding specificity, the brain sections were first stained with **HYR-27** or **HYR-27** + Cu(II), and sequentially immunostained with CF594-labeled HJ3.4 antibodies, which can bind to all A $\beta$  species.<sup>17</sup> The fluorescence images show that while **HYR-27** does not show any colocalization with the HJ3.4 antibodies, in the presence of Cu(II), the hydrolysed product of **HYR-27** shows a significantly increased fluorescence intensity that is colocalized with the HJ3.4 antibodies (Fig. 4), showing that **HYR-27** has a high Cu-responsive ability that could be utilized to detect the Cu-A $\beta$  amyloid plaques present in the 5xFAD brain sections.

Since the chelation of Cu(II) can facilitate the hydrolysis of the picolinic ester bond, a strong Cu(II)-binding chelator, Me<sub>2</sub>HTACN, was introduced to the **HYR-27** fragment, to generate **HYR-27-TACN** (Fig. 5). However, when Cu(II) was added to **HYR-27-TACN**, the fluorescence intensity decreased




**Fig. 5** Cu(II) fluorescence turn-on effects of **HYR-27-TACN**. [HYR-27-TACN] = 50  $\mu$ M, [Cu] = 500  $\mu$ M in PBS (pH = 7.4).

significantly, suggesting that in this case, Cu(II) ions bind strongly to the TACN group and cause paramagnetic quenching of the fluorescence intensity of **HYR-27-TACN**, instead of catalysing the hydrolysis reaction of the picolinic ester group. Thus, these results suggest that the use of strong Cu chelators may not be optimal for the design of Cu(II)-activatable fluorescent sensors, and a weaker Cu(II)-binding picolinic ester moiety may suffice to promote the hydrolysis of the ester bond.

After achieving promising results in which **HYR-27** can act as a Cu(II)-activatable fluorescent sensor, a series of curcumin derivatives with high A $\beta$ -binding affinity and near-infrared (NIR) emission properties were functionalized with the Cu(II)-responsive picolinic ester fragment (Scheme 1 and Fig. S1–S3<sup>†</sup>). The syntheses of the curcumin precursors **YL-1**, **YL-3**, and **YL-5** were carried out by following previously reported procedures,<sup>32</sup> and the final Cu(II)-responsive curcumin derivatives **YL-2**, **YL-4**, and **YL-6** were synthesized *via* an EDC-mediated coupling reaction between 2-picolinic acid and the curcumin precursors.<sup>31</sup>

To confirm the Cu-activatable ability of the developed curcumin derivatives, fluorescence turn-on experiments were performed. Since the solubility of the compounds is poor in PBS, methanol was selected as the solvent to perform the Cu(II) turn-on assays. Notably, in the presence of Cu(II), the curcumin derivatives **YL-2**, **YL-4**, and **YL-6** exhibit a significant fluorescence turn-on signal, proving that the



**Scheme 1** Synthesis of curcumin Cu(II)-activatable sensors.






Fig. 6 Evaluation of Cu(II) fluorescence turn-on effects for a) YL-1 and YL-2, and b) YL-3–YL-6. [YL-X] = 1 or 10  $\mu\text{M}$ , [Cu] = 1 or 10  $\mu\text{M}$  in MeOH.




Fig. 7 Fluorescence microscopy images of 5xFAD mouse brain sections incubated with YL-4 (left panels) and YL-4 + Cu(II) (right panels). [YL-4] = 50  $\mu\text{M}$ , [Cu] = 50  $\mu\text{M}$ . Scale bar (20 $\times$ ): 125  $\mu\text{m}$ .

developed curcumin-based compounds can be activated by Cu(II) ions (Fig. 6a and b, respectively).

To investigate the Cu-activatable activity of the curcumin derivatives towards amyloid plaques, fluorescence staining studies of 5xFAD brain sections were performed with YL-4, since YL-4 exhibited the highest solubility in aqueous media. Upon staining of the brain sections with YL-4 only, the fluorescence images show that YL-4 can stain the amyloid plaques on the brain sections (Fig. 7). However, the fluorescence intensity of the YL-4-stained amyloid plaques is low, and it seems that YL-4 can only stain the core regions of the amyloid plaques. By comparison, upon addition of Cu(II) to the staining solution of the 5xFAD brain sections, the fluorescence intensity of the compound-stained amyloid plaques significantly increases, indicating that YL-4 is efficiently activated by Cu(II) to generate the more highly fluorescent curcumin derivative YL-3. Interestingly, upon incubation with YL-4 and Cu(II), the resulting YL-3 compound seems to also stain the periphery of the amyloid plaques where the A $\beta$  oligomers and smaller A $\beta$  aggregates are usually found, suggesting that these compounds have the potential to detect Cu-A $\beta$  oligomers *ex vivo*. Overall, these brain section staining studies clearly demonstrate that YL-4 can be utilized as a Cu-responsive sensor for the detection of Cu-rich A $\beta$  aggregates of various sizes.

In conclusion, we rationally designed and synthesized a series of Cu-activatable sensors to detect Cu-A $\beta$  species *in vitro* and *ex vivo*. With the introduction of the picolinate ester moiety attached to an A $\beta$ -binding fragment, these developed fluorescent sensors can chelate Cu(II) to facilitate the hydrolysis of the ester bond and release the highly fluorescent A $\beta$ -binding molecule *in vitro*. Furthermore, the Cu-responsive sensors can also react with Cu-A $\beta$  oligomers and fibrils, resulting in a significant fluorescence turn-on, and indicating that the probes are able to detect Cu-A $\beta$  species *in vitro*. To confirm the A $\beta$ -binding specificity of the probes, transgenic AD mouse brain section imaging studies were also performed. As expected, if the brain sections were only stained with the compounds, the fluorescence images show that the sensor has a poor ability to detect amyloid plaques, exhibiting a low fluorescence intensity. However, in the presence of Cu(II) ions, the resulting fluorescence images clearly demonstrate that the sensors are activated by the Cu(II) ions and generate highly fluorescent amyloid-binding fluorophores, which can specifically label the amyloid plaques in the 5xFAD mouse brain sections. Overall, the developed Cu-activatable sensors can be utilized to detect Cu-A $\beta$  species, both *in vitro* and *ex vivo*.

## Conflicts of interest

There are no conflicts to declare.

## References

- 2021 Alzheimer's disease facts and figures, *Alzheimer's Dementia*, 2021, 17, 327–406.
- S. Tiwari, V. Atluri, A. Kaushik, A. Yndart and M. Nair, *Int. J. Nanomed.*, 2019, 14, 5541–5554.
- K. P. Kepp, *Coord. Chem. Rev.*, 2017, 351, 127–159.
- K. P. Kepp, *Chem. Rev.*, 2012, 112, 5193–5239.
- C. J. Maynard, A. I. Bush, C. L. Masters, R. Cappai and Q. X. Li, *Int. J. Exp. Pathol.*, 2005, 86, 147–159.
- M. A. Smith, G. Perry, P. L. Richey, L. M. Sayre, V. E. Anderson, M. F. Beal and N. Kowall, *Nature*, 1996, 382, 120–121.
- D. P. Smith, G. D. Ciccotosto, D. J. Tew, M. T. Fodero-Tavoletti, T. Johanssen, C. L. Masters, K. J. Barnham and R. Cappai, *Biochemistry*, 2007, 46, 2881–2891.
- B. Alies, C. Bijani, S. Sayen, E. Guillon, P. Faller and C. Hureau, *Inorg. Chem.*, 2012, 51, 12988–13000.
- J. T. Pedersen, J. Ostergaard, N. Rozlosnik, B. Gammelgaard and N. H. Heegaard, *J. Biol. Chem.*, 2011, 286, 26952–26963.
- S. Bagheri, R. Squitti, T. Haertle, M. Siotto and A. A. Saboury, *Front. Aging Neurosci.*, 2017, 9, 446.
- G. z. Eskici and P. H. Axelsen, *Biochemistry*, 2012, 51, 6289–6311.
- A. K. Sharma, S. T. Pavlova, J. Kim, D. Finkelstein, N. J. Hawco, N. P. Rath, J. Kim and L. M. Mirica, *J. Am. Chem. Soc.*, 2012, 134, 6625–6636.



- 13 Y. Zhang, D. L. Rempel, J. Zhang, A. K. Sharma, L. M. Mirica and M. L. Gross, *Proc. Natl. Acad. Sci. U. S. A.*, 2013, **110**, 14604–14609.
- 14 A. K. Sharma, S. T. Pavlova, J. Kim, J. Kim and L. M. Mirica, *Metallomics*, 2013, **5**, 1529–1536.
- 15 A. K. Sharma, J. Kim, J. T. Prior, N. J. Hawco, N. P. Rath, J. Kim and L. M. Mirica, *Inorg. Chem.*, 2014, **53**, 11367–11376.
- 16 A. K. Sharma, J. W. Schultz, J. T. Prior, N. P. Rath and L. M. Mirica, *Inorg. Chem.*, 2017, **56**, 13801–13814.
- 17 H.-J. Cho, A. K. Sharma, Y. Zhang, M. L. Gross and L. M. Mirica, *ACS Chem. Neurosci.*, 2020, **11**, 1471–1481.
- 18 C. Esmieu, D. Guettas, A. Conte-Daban, L. Sabater, P. Faller and C. Hureau, *Inorg. Chem.*, 2019, **58**, 13509–13527.
- 19 C. Hureau, *J. Biol. Inorg. Chem.*, 2017, **22**, S230–S230.
- 20 H. J. Yu, W. Zhao, Y. Zhou, G. J. Cheng, M. Sun, L. Wang, L. Yu, S. H. Liang and C. Z. Ran, *Anal. Chim. Acta*, 2020, **1097**, 144–152.
- 21 T. Hirayama, G. C. Van de Bittner, L. W. Gray, S. Lutsenko and C. J. Chang, *Proc. Natl. Acad. Sci. U. S. A.*, 2012, **109**, 2228–2233.
- 22 S. Lee, C. Y. S. Chung, P. Liu, L. Craciun, Y. Nishikawa, K. J. Bruemmer, I. Hamachi, K. Saijo, E. W. Miller and C. J. Chang, *J. Am. Chem. Soc.*, 2020, **142**, 14993–15003.
- 23 K. J. Bruemmer, S. W. M. Crossley and C. J. Chang, *Angew. Chem., Int. Ed.*, 2020, **59**, 13734–13762.
- 24 D. A. Iovan, S. Jia and C. J. Chang, *Inorg. Chem.*, 2019, **58**, 13546–13560.
- 25 H. Li, P. Zhang, L. P. Smaga, R. A. Hoffman and J. Chan, *J. Am. Chem. Soc.*, 2015, **137**, 15628–15631.
- 26 M. Saleem, M. Rafiq, M. Hanif, M. A. Shaheen and S. Y. Seo, *J. Fluoresc.*, 2018, **28**, 97–165.
- 27 L. Zeng, E. W. Miller, A. Pralle, E. Y. Isacoff and C. J. Chang, *J. Am. Chem. Soc.*, 2006, **128**, 10–11.
- 28 D. W. Domaille, L. Zeng and C. J. Chang, *J. Am. Chem. Soc.*, 2010, **132**, 1194–1195.
- 29 B. Muthuraj, S. Layek, S. N. Balaji, V. Trivedi and P. K. Iyer, *ACS Chem. Neurosci.*, 2015, **6**, 1880–1891.
- 30 Y. Y. Yu, P. Wang, X. D. Zhu, Q. W. Peng, Y. Zhou, T. X. Yin, Y. X. Liang and X. X. Yin, *Analyst*, 2018, **143**, 323–331.
- 31 See ESI.†
- 32 K. Liu, J. M. Chen, J. Chojnacki and S. J. Zhang, *Tetrahedron Lett.*, 2013, **54**, 2070–2073.

